
    
      This is a phase I, open label study of the safety and pharmacokinetics of T2-18C3 in patients
      with T2D. Nine patients will receive four biweekly IV infusions of the study drug, T2-18C3,
      at a dose level of 1.25 mg/kg. These patients will be followed for a total of 90 days to
      examine safety, pharmacokinetics, and preliminary efficacy.
    
  